Eularis
Eularis is a private biopharma AI strategy and governance advisory firm founded in 2003, serving pharmaceutical, biotechnology, and hospital network clients globally. It sells consulting engagements, board-level advisory, training programs, and subscription memberships rather than AI software, with deep regulatory expertise across FDA, EMA, and EU AI Act frameworks.
- Company typePrivate
- Founded2003
- HeadquartersNew York, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Eularis does
Eularis is a privately held strategy and governance advisory firm focused exclusively on biopharma and life sciences organizations. Founded in 2003 by Dr. Andrée Bates, the firm is headquartered in London with offices in New York and operates across the US, UK, Switzerland, Japan, and Australia. It does not sell AI software; instead it sells the strategic, governance, and human foundation that makes AI work in FDA-regulated pharma environments.
The firm's core offering is organized around four entry points — AI Strategy, AI Governance (a three-tier program covering Assessment, Foundation, and Managed Service aligned to FDA, EMA, EU AI Act, ISO 42001, and NIST AI RMF), Strategic AI Intelligence (The Bates Briefing), and AI Capability Building (Pharma AI Institute and the AI For Pharma Leaders Masterclass). These are supported by three service modules: REVEAL Lab (AI-powered commercial problem solving), ACCELERATE Lab (foundational readiness for AI projects), and the Transformation Engine (future-proof strategy). Proprietary methodologies are a key technical component, even though no software product is shipped.
Revenue is generated through professional services engagements (board-level advisory capped at 4-6 active relationships, AI Strategy Diagnostic Sprints, Strategic Assessments, and full AI Strategic Blueprints), training programs and speaking engagements, and two subscription streams (AI-cademy membership and The Bates Briefing). Pricing is not publicly disclosed. Named enterprise customers include Pfizer, Merck Japan, Novo Nordisk, Takeda Pharmaceuticals, and Eurocine Vaccines. The firm is bootstrapped with no disclosed external funding, no public listing, and no M&A activity, with founder involvement remaining central to client delivery.
Eularis firmographics
Firmographics- Name
- Eularis
- Legal name
- Eularis Limited
- Website
- https://eularis.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Eularis is a private biopharma AI strategy and governance advisory firm founded in 2003, serving pharmaceutical, biotechnology, and hospital network clients globally. It sells consulting engagements, board-level advisory, training programs, and subscription memberships rather than AI software, with deep regulatory expertise across FDA, EMA, and EU AI Act frameworks.
- Ownership category
- akta.pro rank
Eularis industry classification
Industry- Product category
- Pharmaceutical AI Consulting
- NAICS
- Management, Scientific, and Technical Consulting Services (5416)
- SIC
- Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Responsible AI, AI Governance & Compliance Services (BPAEAHAJ)
- akta.pro secondary industries
- Regulatory Readiness & Audit Automation (e.g., EU AI Act, NIST AI RMF, ISO/IEC 42001) (HDAAAMAE), Enterprise AI Governance, Risk & Compliance Platforms (Model Risk, Audit, Policies) (HDAEANAE)
Keywords
Where Eularis is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Eularis business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Strategic Consulting Engagements: AI Strategy and Governance consulting engagements including AI Strategy Diagnostic Sprint (2-week engagement), Strategic Assessment, and full AI Strategic Blueprint development with corporate financial modelling
- AI-cademy Membership: Subscription membership providing success pathways, resources, tools, big data access, CEO roundtables, and personalized support for healthcare leaders. Monthly and annual billing options available
- AI Training Programs: AI For Pharma Leaders Masterclass (2-day intensive training), Pharma AI Institute, virtual live training, and speaking engagements for conferences and internal events
- Board-Level Advisory: Dr. Bates provides board-level advisory to small number of pharma and biotech companies on AI strategy, governance, and capital allocation (limited to 4-6 active relationships)
- The Bates Briefing: Strategic AI intelligence publication for pharma leadership - written analysis, monthly videos, quarterly reports and exec sessions
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | AI-cademy Membership - Monthly |
| Subscription | Annual | AI-cademy Membership - Annual |
| Other | Multi-year contract | AI Strategy Diagnostic Sprint |
| Subscription | Multi-year contract | AI For Pharma Leaders Masterclass |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
Eularis product offering
Product offeringCore offering
Eularis is a strategic AI consulting and advisory firm that guides pharmaceutical, biotechnology, and large healthcare organizations through AI strategy, governance, and capability building. The firm delivers board-defensible AI governance frameworks aligned with FDA, EMA, EU AI Act, ISO 42001, and NIST AI RMF, along with AI strategy diagnostic sprints, executive advisory, and AI training programs. Rather than selling AI tools, Eularis builds the strategic and human foundations that make AI adoption succeed in regulated biopharma environments.
Product overview
Eularis is a strategic AI consulting and advisory firm for biopharma and life sciences organisations, offering a portfolio of services rather than a single software product. The core offering includes four main entry points: AI Strategy (identifying optimal AI paths for impact), AI Governance (board-defensible governance frameworks covering FDA, EMA, EU AI Act, ISO 42001, NIST AI RMF), Strategic AI Intelligence (The Bates Briefing - written analysis and reports by Dr. Andrée Bates), and AI Capability Building (Pharma AI Institute training). These are supplemented by three service labs: REVEAL LAB (solving complex commercial challenges), ACCELERATE LAB (foundational project elements), and TRANSFORMATION ENGINE (future-proofing strategy). Additional offerings include the AI-cademy membership platform, AI Mentoring, the AI Strategy Diagnostic Sprint, the AI For Pharma Leaders Masterclass, AI Speaking Engagements, and the AI For Pharma Growth Podcast. The company does not sell AI tools but builds strategic and human foundations for AI adoption.
Differentiator
Problem solved
Functional benefit
Brands
- AI-cademy: Membership platform providing AI training and resources for healthcare leaders, including success pathways, big data access, and CEO roundtables on AI.
- The Bates Briefing
- Reveal Lab
- Accelerate Lab
- Transformation Engine
Products and services
- AI Strategy
Quantifiable outcome
- 0% of launch drugs Eularis has worked on have become top brands within 1 year
- +1 more outcomes
Companies that use Eularis
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
Eularis technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Eularis partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- DrugBankcoreDr. Andrée Bates (founder of Eularis) serves as an inaugural member of DrugBank's Advisory Board to guide AI adoption in the biopharma industry. DrugBank positions structured, expert-validated data as the foundation biopharma organizations need to ensure AI credibility in scientific and medical workflows. The board addresses the gap between record-level AI investment and lagging data infrastructure within a 12-month window.
Scale indicators5 records
Recent moves5 records
Expansion highlights6 records
Eularis competitors and assessment
Company assessmentBroad incumbents
- Bain & Company (Healthcare & Life Sciences): Global strategy consulting firm with a healthcare and life sciences practice serving pharma commercial strategy and AI-driven transformation — comparable in serving top pharma on strategy, broader in scope.
- Charles River Associates (Life Sciences practice): Global consulting firm with a dedicated life sciences practice serving pharma and biotech strategy, economics, and analytics — comparable in serving pharma strategy and commercial analytics buyers, with broader corporate scope.
- Inizio Evoke (formerly known as Ashfield Health / Real Chemistry): Large health communications and commercialization services group serving pharma commercial, marketing, and AI-driven engagement — comparable in serving pharma commercial and marketing analytics buyers as part of a wider commercialization portfolio.
- IQVIA: Large life sciences technology and analytics provider offering commercial strategy, real-world evidence, and AI/data services to pharma — comparable in serving pharma commercial and analytics buyers but at vastly greater scale and breadth.
- McKinsey & Company (Pharma & Medical Products practice): Global management consultancy with a major pharma and medical products practice — comparable in delivering AI strategy and governance to pharma leadership, though as part of a much broader consulting portfolio.
- Accenture (Life Sciences): Global professional services firm with a dedicated life sciences practice delivering digital, data, and AI strategy — comparable in serving large pharma on AI strategy and digital transformation, but at much larger scale and as part of broader services.
Direct peers
- Trinity Partners: Specialized strategy consulting firm for life sciences, focused on commercial strategy and analytics for pharma and biotech — directly comparable boutique peer with similar therapeutic-area and commercial strategy focus.
- ZS Associates: Global consulting firm deeply focused on pharma and biopharma sales, marketing, and analytics — directly comparable to Eularis in serving pharma commercial strategy and AI-driven analytics buyers, with significantly larger scale.
- Health Advances: Specialized healthcare and life sciences strategy consulting firm focused on pharma, biotech, and medical technology — directly comparable niche consultancy serving similar pharma strategy buyers.
- Putnam Associates: Life sciences strategy consulting firm serving pharma and biotech commercial strategy and access engagements — directly comparable niche consultancy with overlapping pharma commercial and market access expertise.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Eularis social profiles
Digital presenceEularis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Eularis leadership team
Management profileNumber of profiles
Profiles1 record
Eularis funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Eularis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Eularis
What does Eularis do?
Eularis is a strategic AI consulting and advisory firm that guides pharmaceutical, biotechnology, and large healthcare organizations through AI strategy, governance, and capability building. The firm delivers board-defensible AI governance frameworks aligned with FDA, EMA, EU AI Act, ISO 42001, and NIST AI RMF, along with AI strategy diagnostic sprints, executive advisory, and AI training programs. Rather than selling AI tools, Eularis builds the strategic and human foundations that make AI adoption succeed in regulated biopharma environments.
Is Eularis a public or private company?
Eularis is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Eularis founded?
Eularis was founded in 2003. It employs 101 to 250 people.
Where is Eularis based?
Eularis is headquartered in New York, United States, in the North America region.
How does Eularis make money?
Five revenue lines are on record. Strategic Consulting Engagements are the primary driver. The others are AI-cademy Membership, AI Training Programs, board-Level Advisory and the Bates Briefing.
Who are Eularis's main competitors?
Broad incumbents on record are Bain & Company (Healthcare & Life Sciences), Charles River Associates (Life Sciences practice), Inizio Evoke (formerly known as Ashfield Health / Real Chemistry), IQVIA, McKinsey & Company (Pharma & Medical Products practice) and Accenture (Life Sciences). Direct peers are Trinity Partners, ZS Associates, Health Advances and Putnam Associates.
Does Eularis have an API?
No public API is recorded for Eularis.
What industry is Eularis in?
Eularis's product category is Pharmaceutical AI Consulting. Its primary akta.pro industry code is BPAEAHAJ, Responsible AI, AI Governance & Compliance Services, with a secondary code of HDAAAMAE, Regulatory Readiness & Audit Automation (e.g., EU AI Act, NIST AI RMF, ISO/IEC 42001). Its NAICS code is 5416 and its SIC code is 7370.